|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM210589434 |
| 003 |
DE-627 |
| 005 |
20231224011933.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2011 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2011.06.009
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0702.xml
|
| 035 |
|
|
|a (DE-627)NLM210589434
|
| 035 |
|
|
|a (NLM)21824820
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Aubin, Éric
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Prevention of T cell activation by interference of internalized intravenous immunoglobulin (IVIg) with MHC II-dependent native antigen presentation
|
| 264 |
|
1 |
|c 2011
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.01.2012
|
| 500 |
|
|
|a Date Revised 17.03.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2011 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Activation of self-reactive CD4(+) T cells plays a central role in the initiation and maintenance of autoimmune diseases. We recently reported that intravenous immunoglobulin (IVIg) inhibits the MHC II-restricted CD4(+) T cell activation induced by the presentation of immune complexes. Because native antigens can also play a role in the induction of several autoimmune diseases, we determined whether IVIg could also affect CD4(+) T cell activation following presentation of native antigens by APCs. Here we report that IVIg significantly reduces the activation of CD4(+) T cells by native ovalbumin. The inhibitory effect is FcγR-independent and occurs following internalization of IVIg inside APCs, where it interferes with the intracellular events leading to MHC II-dependent antigen presentation. The effect of IVIg on native antigen presentation could therefore contribute to dampen the autoimmune reaction by reducing CD4(+) T cell activation and the subsequent inflammatory response induced by these cells
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Histocompatibility Antigens Class II
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulins, Intravenous
|2 NLM
|
| 650 |
|
7 |
|a Ovalbumin
|2 NLM
|
| 650 |
|
7 |
|a 9006-59-1
|2 NLM
|
| 700 |
1 |
|
|a Proulx, Dominic Paquin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Trépanier, Patrick
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lemieux, Réal
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bazin, Renée
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 141(2011), 3 vom: 01. Dez., Seite 273-83
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:141
|g year:2011
|g number:3
|g day:01
|g month:12
|g pages:273-83
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2011.06.009
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 141
|j 2011
|e 3
|b 01
|c 12
|h 273-83
|